Clinical Trials In Quebec City
Discover hundreds of clinical trials in Quebec City.
Search clinical trials in Quebec City by condition or phase.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
Hypofractionated LocoRegional Radiotherapy in Breast Cancer
Sponsor:
Ontario Clinical Oncology Group (OCOG)
Location:
Code:
NCT04228991
Conditions
Breast Neoplasms
Radiotherapy
Lymphedema
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Locoregional radiation treatment - Conventional fractionation
Locoregional radiation treatment - Hypofractionation
EPI-STORM: Cytokine Storm in Organ Donors
Sponsor:
Université de Sherbrooke
Location:
Code:
NCT03786991
Conditions
Organ Donation
Liver Transplantation
Kidney Transplantation
Graft Dysfunction
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
No intervention
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
Product Surveillance Registry
Sponsor:
Medtronic
Location:
Code:
NCT01524276
Conditions
Cardiac Rhythm Disorders
Urological Disorders
Neurological Disorders
Cardiovascular Disorders
Digestive Disorders
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Evaluation of A Clinical Diagnostic Test for CRDS
Sponsor:
Population Health Research Institute
Location:
Code:
NCT06188689
Conditions
Calcium Release Deficiency Syndrome (CRDS)
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Pacing
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
Sponsor:
AstraZeneca
Location:
Code:
NCT05692180
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 6 - 18
Healthy Volunteers: Not accepted
Interventions
Benralizumab
Placebo
A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06435273
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
AZD4604
Placebo to AZD4604
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06305767
Conditions
Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
V940
Placebo
Enfortumab Vedotin
Surgery (RC plus PLND)